Stage 0 Invasive Ductal Carcinoma: Erica's Survivor Story

Patient Info: Erica Newbert Campbell, Female | Stage 0

Biomarkers: BRCA1/2-negative

As of June 2024, about 6 years after Stage 0 DCIS diagnosis, Erica described her body and mind as cancer-free after double mastectomy and reconstruction.

The Patient StoryRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Liz's Patient Story

Patient Info: Liz O'Riordan, Female, 40s | Stage III

Biomarkers: ER-positive; HER2-negative; PIK3CA mutation reported by patient

As of June 2024, Liz described Stage III ER-positive/HER2-negative mixed ductal and lobular breast cancer followed by 2 locoregional recurrences after mastectomy; no distant metastatic disease was described for her personal story.

YouTube — Dr Liz O'RiordanRead more →

Breast Cancer and a Rare Benign Blood-Vessel Growth Found in the Same Lymph Node

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-negative

A 47-year-old woman with hormone receptor-positive, HER2-negative breast cancer had five involved axillary lymph nodes, including one that also contained a rare benign hemangioma.

PubMed CentralRead more →

Secretory Breast Carcinoma With Apocrine Differentiation in a 72-Year-Old Woman

Patient Info: Anonymized, female, 70+

Biomarkers: ER and PR positive in the microcystic component and negative in the solid component; AR-positive in the solid component

More than 1 year after diagnosis, she was alive and under long-term surveillance after surgery.

PubMed CentralRead more →

Invasive Lobular Carcinoma: Kim's Survivor Story

Patient Info: Kim, Female

Biomarkers: ER 99% positive; PR 85% positive; HER2-negative

Kim’s ER-positive, PR-positive, HER2-negative ILC responded strongly to Zoladex and Letrozole before skin-sparing mastectomy, with 90% tumor necrosis, clear margins, no lymph node spread, and confirmation that she was cancer-free.

Lobular Breast Cancer AllianceRead more →

Primary breast angiosarcoma: R0 resection, disease-free at 6 months

Patient Info: Anonymized, Female, Under 40

Biomarkers: ERG-positive; Ki-67 50%

Disease-free 6 months after skin-sparing mastectomy with R0 resection for localized primary breast angiosarcoma; continued close 3-month surveillance after declining further treatment.

PubMed CentralRead more →

Stage 2 triple-negative breast cancer: pathologic complete response to chemotherapy

Patient Info: Anonymized, Female, 40s | Stage II

Biomarkers: Triple-negative breast cancer, with pathogenic PALB2 c.1451T>A variant found in blood/buccal/tumor testing.

As of May 2024, more than 1 year after surgery, she was well and free of cancer after neoadjuvant chemotherapy, mastectomy, reconstruction, and preventive adnexectomy.

PubMed CentralRead more →

Secretory breast cancer: mastectomy and radiotherapy to no evidence of disease

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 50%; tumor-infiltrating lymphocytes 60%

As of May 2024, 6 months after mastectomy and adjuvant radiotherapy for pT2N0M0 triple-negative secretory breast cancer, clinical examination and imaging showed no evidence of relapse.

PubMed CentralRead more →

Stage III Inflammatory Breast Cancer: Katrece's Patient Story

Patient Info: Katrece Nolen, Female | Stage III

More than 10 years after her diagnosis, Katrece was taking medication intended to reduce recurrence risk and remained active in advocacy for people with inflammatory breast cancer.

Stage IV Invasive Lobular Carcinoma: Melissa's Patient Story

Patient Info: Melissa Adams, Female | Stage IV

Melissa’s breast cancer progressed after maintenance hormone therapy and was reassigned as Stage IV. She describes living with incurable disease while focusing on keeping the cancer at bay and staying engaged with family, church, and advocacy.

HER2-Positive Breast Cancer: Irasema's Survivor Story

Patient Info: Irasema Partida Chavez, Female

Biomarkers: HER2-positive

Irasema reported no evidence of breast cancer for 3 years after surgery and HER2-targeted treatment.

Triple-negative metaplastic breast cancer with complete pathologic response to chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 <10%; CK-positive; S100-positive; focal vimentin-positive

At 1-year follow-up, there were no signs of recurrence after doxorubicin/cyclophosphamide chemotherapy and modified radical mastectomy with complete pathologic response.

PubMed CentralRead more →

MSI-High Metastatic Hormone-Receptor-Positive Breast Cancer Responding to Pembrolizumab

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; MSI-high; BRCA mutation-negative

Metastatic Site: bone, para-aortic lymph nodes, brain

Pembrolizumab produced marked improvement in metastatic bone and nodal disease. After 1 year it was stopped because of appetite loss; 8 months later she was symptom-free and back at work on endocrine therapy, although asymptomatic brain metastases were documented.

PubMed CentralRead more →

Triple-negative breast cancer and ovarian cancer treated with chemotherapy and PARP inhibitor

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Germline pathogenic BRCA2 c.6468_6469del; breast tumor triple-negative

As of April 2024, 6-week follow-up after breast and nodal radiation was unremarkable, erythema had resolved, and no breast, chest wall, respiratory, or axillary abnormality was found; longer-term control was not reported.

PubMed CentralRead more →

Freezing treatment (cryoablation) used to manage slow-growing triple-negative breast cancer

Patient Info: Anonymized, Female | Stage Metastatic/Advanced

Biomarkers: ER-negative; PR-negative; HER2-negative; androgen receptor-positive in original tumor; Ki-67 5% initially and 10% at recurrence

At 29 months after recurrence diagnosis and 20 months after the first cryoablation, no viable breast tumor was seen at treated sites, axillary nodes were unchanged, pain was absent, and she remained active and independent.

PubMed CentralRead more →

Metastatic Breast Cancer With Recurrent Severe Hypocalcemia During Treatment - Case 1

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: bone, liver, ovaries

She died about 9 years after her breast-cancer diagnosis after progression of liver metastases.

PubMed CentralRead more →

HER2-Positive Metastatic Breast Cancer With Recurrent Severe Hypocalcemia - Case 2

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: bone, liver

She died about 7 years after her breast-cancer diagnosis after rapid deterioration from liver metastases.

PubMed CentralRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Allison's Patient Story

Patient Info: Allison Tierney, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; CHEK2 mutation; BRCA1/2 negative

As of March 2024, Allison had completed Taxol and Herceptin treatment, was on tamoxifen planned for 10 years, and had moved to 6-month oncology follow-up. No metastatic disease or recurrence was reported.

YouTube — The Patient StoryRead more →

Stage III Invasive Lobular Carcinoma: Harvey's Patient Story

Patient Info: Harvey, Male, 50s | Stage III

Biomarkers: Genetic testing negative

Harvey was in active treatment for male Stage IIIC grade 3 ILC after right mastectomy and initiation of AC-T chemotherapy, with radiation and endocrine/targeted therapy planned as of March 2024.

Lobular Breast Cancer AllianceRead more →

Stage II Triple-Negative Breast Cancer: Chance's Survivor Story

Patient Info: Chance Osborne, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of March 2024, Chance Osborne was a young Stage II TNBC survivor with a BRCA1 mutation, sharing her experience with chemotherapy, double mastectomy recovery, and advocacy.

Recurrent Lobular Breast Cancer Appears in the Skin Alongside Pyoderma Gangrenosum

Patient Info: Anonymized, female, 70+

Recurrent cutaneous lobular carcinoma was confirmed on the anterior chest wall, and she died soon after the dermatology evaluation before additional cancer treatment began.

PubMed CentralRead more →

Left Breast Cancer in a BRCA2 Carrier Treated With Mastectomy, Chemotherapy, and an Arm Port

Patient Info: Anonymized, female, Under 40

Biomarkers: Hormone receptor-positive; HER2-negative; pathogenic BRCA2 variant

At 17 months after surgery, she was free from disease and reported good quality of life and satisfaction with reconstruction and the arm port.

PubMed CentralRead more →

Occult Right Breast Cancer Found During BRCA2 Risk-Reducing Mastectomy

Patient Info: Anonymized, female, Under 40

Biomarkers: Hormone receptor-positive; HER2-negative; pathogenic BRCA2 variant

At the overall 17-month follow-up after bilateral surgery, she was free from disease.

PubMed CentralRead more →

Breast Cancer Survivor Develops Painful Scar Calcifications 15 Years After Treatment

Patient Info: Anonymized, female

Biomarkers: Triple-negative

About 20 years after her 2003 diagnosis, tissue removed during the 2022-2023 scar surgeries showed dystrophic calcifications and inflammation without signs of cancer.

PubMed CentralRead more →